1427518-58-8

Basic information

• Product Name: C₂₀H₂₇ClN₆O₂
• Synonyms: C₂₀H₂₇ClN₆O₂
• CAS NO: 1427518-58-8
• Molecular Weight: 418.926
• Mol File: 1427518-58-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₀H₂₇ClN₆O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₀H₂₇ClN₆O₂(1427518-58-8)
• EPA Substance Registry System: C₂₀H₂₇ClN₆O₂(1427518-58-8)

Safety Data

• Hazardous Substances Data: 1427518-58-8(Hazardous Substances Data)

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 74608-26-7 (1S)-2-hydroxy-1,2-dimethylpopylamine 
• 1427518-62-4 4-chloro-2-[(2-chloro-9-isopropyl-9H-purin-6-ylamino)-methyl]-phenol 

Relevant articles and documents

Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases

Several inhibitors of cyclin-dependent kinases (CDKs), including the 2,6,9-trisubstituted purine derivative roscovitine, are currently being evaluated in clinical trials as potential anticancer drugs. Here, we describe a new series of roscovitine derivatives that show increased potency in vitro. The series was tested for cytotoxicity against six cancer cell lines and for inhibition of CDKs. For series bearing 2-(hydroxyalkylamino) moiety, cytotoxic potency strongly correlated with anti-CDK2 activity. Importantly, structural changes that increase biochemical and anticancer activities of these compounds also increase elimination half-life. The most potent compounds were investigated further to assess their ability to influence cell cycle progression, p53-regulated transcription and apoptosis. All the observed biological effects were consistent with inhibition of CDKs involved in the regulation of cell cycle and transcription.